Interestingly, the inhibition of the mTOR pathway with rapamycin reverses the senescent phenotype and results in reduced SA‐βgal staining and p16INK4a expression levels in iPSC‐derived NPC from MS patients. The gene discussed is MTOR; the disease is myeloid sarcoma.